hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 02:48:07 - browse：7

Pfizer plans to exit a major biotechnology industry trade association. Cindy Ord/Getty Images for Pfizer/BioNTech

WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the planning.

The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.

“The economic situation for the industry is difficult indeed and we of course are disappointed that any company would be forced to take a break from its BIO membership. We certainly hope that when economic conditions improve, we can welcome those companies back and welcome new members to join us as well, but it in no way affects our mission of protecting patients and medical innovation in the United States,” said BIO’s Chief Public Affairs and Marketing Officer Rich Masters. Masters said he wouldn’t comment on the status of any particular member.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Industry veterans launch new biotech VC with $310M

WSS

Industry veterans launch new biotech VC with $310M

To avoid data mishandling cases, universities eye AI and other tools

Shingles, which affected Dianne Feinstein, is on the rise

Ionis has late

Cigna to pay $172 million to settle Medicare Advantage fraud probe

FDA seeks to regulate lab

leisure time

hotspot

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Listen: Who gets the credit for GLP

Guidelines to prevent youth baseball injuries need more muscle

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare drug price negotiation program allowed for now

Medical records are filled with copy

FDA seeks to regulate lab

How one medical school became remarkably diverse

Private equity deals in Medicare Advantage declines

focus

Would Medicare drug price negotiations stall in a shutdown?

Sudafed saga points to U.S. issues with evaluating older drugs

Readout LOUD podcast: How biotech is using artificial intelligence

BioAge raises $170M for combination therapy with Zepbound

After a drawn out lobbying fight, ARPA

What should King Charles tell the public about his cancer?

leisure time

knowledge

entertainment

Wikipedia